Market Feedback

Report
August 2024

© 2022. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
Disclaimer

IQVIA is not an “authorised person” for the purposes of the Financial Services
and Markets Act 2000 (“FSMA”) and does not provide investment advice or carry
on any other regulated activity under Part II of the FSMA 2000 (Regulated
Activities) Order 2001
The forecasts, projections, and related information contained herein are made
and provided subject to the assumptions, methodologies, caveats, and variables
described in this report and are based on third party sources and data
reasonably believed to be reliable. No warranty is made as to the completeness
or accuracy of such third-party sources or data
This report, in part or in whole, is not intended to constitute investment advice,
and is not a recommendation to purchase or not purchase, an endorsement of,
or an opinion as to the value of, any security or any investment instrument of any
entity
As with any attempt to estimate future events, the forecasts, projections,
conclusions, and other information included herein are subject to certain risks
and uncertainties, and are not to be considered guarantees of any particular
outcome
This report shall not be published, nor shall any public references to IQVIA be
made regarding these services or this report, without IQVIA’ prior written
approval. When so provided, this report and the information herein must always
be provided and used in its entirety, including this complete Disclaimer page
This report is subject to the IQVIA General Terms and Conditions.

1
Source: IQVIA TSA Dataset Aug'2024
IPM Key Highlights – Aug’24
IPM Growth and Monthly Sale Trend
21,000 20
16.5
15
11.2
10.1 10.3 10.5 9.8 10.1 9.8
20,000 9.0 8.8
7.6 7.6 8.1 10
11.5
8.6 7.9 7.7 7.4 7.4 8.0 7.6 5
5.8 6.7
19,000 5.1
3.5
1.3 0

18,000 -5

-10
17,000
-15

-20
16,000
Nov'23 18,002.3

July'24 19,883.2
Aug'23 18,700.9

Sept'23 19,173.8

Oct'23 18,986.0

Dec'23 18,066.8

Jan'24 17,937.5

Feb'24 17,970.2

Mar'24 17,387.6

Apr'24 19,534.2

May'24 18,915.4

June'24 17,730.0

Aug'24 20,164.0
-25

15,000 -30

Month Value'Cr Month growth MAT growth

• IPM monthly growth decreased to 7.6% for Aug’24 from 11.2% reported
last month.
• MAT growth for Aug’24 was at 8.1%, which is higher than reported for
last five months.

Acute vs. Chronic Trend

270,000

60%
17.8%

220,000
40%
10.2%
13.2% 8.1%
7.2%
4.4% 20%
170,000 12.0%
20.7%
9.0% 10.0%
9.2% 9.2%
6.2% 6.9% 0%
1.7%
120,000

-20%

70,000
-40%
148992.1

175581.8

188247.9

128818.8

207527.3

137686.6

224284.5
117994.5
111150.9
92098.2

56893.9

64430.8

70253.4

78708.6

86597.9

20,000 -60%
MAT Aug'20 MAT Aug'21 MAT Aug'22 MAT Aug'23 MAT Aug'24
ACUTE CHRONIC OVERALL Acute growth Chronic Growth Overall Growth

• Continuing the trend, chronic segment continued to grow faster @ 10%

as compared to acute segment growth of 6.9% for MAT Aug’24.

Source: IQVIA TSA Dataset Aug'2024 2

 Monthly Growth Trends –Aug’24
IPM August month trend as compared to
preceding July month

22,000 40.0%

30.0%

18,000
20.0%
7.3%
6.6% 7.3% 10.0%
14,000 4.3% 5.6% 3.5%

4.4% 4.8%
1.6% 1.4% 0.0%
0.4% 2.6% 0.8%
-2.8% -1.9%
10,000
-10.0%

-20.0%
6,000

-30.0%
13466.8

10442.1

16047.9

11363.3

17673.1

11877.4

18741.0

12678.6

20164.0
8542.4

4924.4

5605.8

6309.8

6863.6

7485.4
2,000 -40.0%
Aug'20 Aug'21 Aug'22 Aug'23 Aug'24

Acute Chronic Overall Acute Growth Chronic Growth Overall Growth

In Aug’24 as compared to July’24, acute segment grew by 3.5% while

chronic segment declined by 1.9% resulting in overall growth of 1.4% only.
The growth in Aug’22 as compared to July’22 was the highest for all
segments as shown in above chart.
IPM August month trend as compared to
August month of previous year

20,000.0 40.0%

18,000.0
22.2%

12.6% 20.0%
16,000.0 8.8%
19.2% 10.1%
9.0% 9.1%
13.8%
14,000.0 6.0% 7.6%
8.8%
-0.2%
6.7%
4.5% 0.0%
12,000.0 -4.9%

10,000.0
-20.0%

8,000.0

6,000.0
-40.0%

4,000.0
13466.8

10442.1

16047.9

11363.3

17673.1

11877.4

18741.0

12678.6

20164.0
8542.4

4924.4

5605.8

6309.8

6863.6

7485.4

2,000.0 -60.0%
Aug'20 Aug'21 Aug'22 Aug'23 Aug'24
Acute Chronic Overall Acute Growth Chronic Growth Overall Growth

Chronic segment has grown faster @ 9.1% for month of Aug’24 as

compared to month of Aug’23. Acute segment grew by 6.7% for the same
period resulting in overall monthly growth of 7.6%.

Source: IQVIA TSA Dataset Aug'2024 3

Top Companies in IPM – Aug’24
RANKING MONTH Aug'24 MAT Aug'24
CORPORATIONS Values In Growth Values In Growth
MAT MON MS % MS % EVOL
Cr % Cr %
IPM 20163.98 100 7.59 224284.53 100 8.07 100
1 1 SUN* 1565.23 7.76 9.73 17475.61 7.79 9.54 101.36
2 2 ABBOTT* 1257.60 6.24 9.41 13901.04 6.20 8.72 100.59
3 3 CIPLA 1045.34 5.18 7.02 12230.86 5.45 7.41 99.38
4 4 MANKIND 900.34 4.47 6.98 9997.21 4.46 9.19 101.03
5 5 ALKEM* 832.58 4.13 5.07 8872.72 3.96 5.85 97.94
6 6 INTAS * 733.93 3.64 11.45 8080.47 3.60 12.29 103.9
7 9 LUPIN 674.25 3.34 8.37 7691.93 3.43 7.85 99.79
8 8 TORRENT * 675.66 3.35 8.23 7655.49 3.41 8.67 100.55
9 7 MACLEODS 679.67 3.37 5.56 7513.11 3.35 9.18 101.02
10 11 DRL 619.15 3.07 8.04 6929.01 3.09 9.28 101.12
11 10 ARISTO * 628.39 3.12 8.09 6491.06 2.89 7.41 99.38
12 12 ZYDUS* 575.28 2.85 9.88 6380.61 2.84 6.80 98.82
13 13 GSK* 457.22 2.27 0.30 5227.11 2.33 1.38 93.8
14 14 EMCURE* 447.38 2.22 4.29 5096.31 2.27 6.60 98.64
15 16 GLENMARK 416.57 2.07 13.50 4703.55 2.10 12.04 103.67
16 15 IPCA LABS 421.94 2.09 9.79 4550.57 2.03 14.81 106.24
17 17 USV 372.17 1.85 7.26 4297.00 1.92 7.07 99.07
18 18 MICRO* 319.69 1.59 3.19 3515.01 1.57 2.85 95.17
19 19 PFIZER* 294.37 1.46 6.14 3342.19 1.49 -0.83 91.76
20 20 ALEMBIC 279.20 1.38 3.18 3243.90 1.45 3.91 96.14
21 21 JB * 239.55 1.19 13.70 2580.38 1.15 10.51 102.25
22 22 FDC 212.80 1.06 7.87 2383.23 1.06 9.81 101.6
23 23 ERIS* 201.85 1.00 4.40 2378.37 1.06 8.94 100.8
24 24 SANOFI* 190.79 0.95 -0.99 2289.13 1.02 5.52 97.64
25 25 HIMALAYA DRUG 159.38 0.79 2.10 1796.03 0.80 7.57 99.53
26 26 AJANTA 148.98 0.74 9.52 1715.62 0.76 9.17 101.01
27 28 LA RENON HEALTHCA. 138.33 0.69 13.33 1615.68 0.72 19.21 110.3
28 27 CADILA 140.76 0.70 5.90 1580.16 0.70 1.40 93.83
29 32 CORONA REMEDIES 117.94 0.58 10.80 1372.04 0.61 14.32 105.78
30 31 FRANCO INDIAN 119.82 0.59 -6.31 1312.58 0.59 -8.80 84.38
31 29 HETERO HEALTHCARE* 126.02 0.62 12.71 1296.38 0.58 10.18 101.95
32 30 INDOCO* 120.66 0.60 4.54 1288.54 0.57 1.30 93.73
33 33 BLUE CROSS 115.42 0.57 2.44 1226.35 0.55 -0.29 92.26
34 34 PROC.&GAMB.HEALTH 108.66 0.54 9.92 1161.01 0.52 -2.01 90.67
35 35 SYSTOPIC 105.44 0.52 10.22 1144.20 0.51 10.70 102.43
36 36 MEDLEY 97.19 0.48 4.24 1049.90 0.47 5.55 97.66
37 37 WIN MEDICARE 90.67 0.45 6.85 972.99 0.43 5.47 97.59
38 38 FOURRTS 83.40 0.41 6.76 950.69 0.42 10.09 101.87
39 39 HEGDE & HEGDE 83.05 0.41 3.83 931.32 0.42 4.15 96.37
40 44 BHARAT SERUM 77.96 0.39 6.85 894.30 0.40 10.59 102.33

Source: IQVIA TSA Dataset Aug'2024 4

Top Brands in IPM – Aug’24
RANKING MONTH Aug'24 MAT Aug'24
MANU
PRODUCTS
(Abbr.) Growth MS Growth
MAT MON Values'Cr MS % Values'Cr EVOL
% % %

IPM 20163.98 100 7.59 224284.53 100 8.07 100

1 3 FORACORT CPL 69.14 0.34 7.08 888.72 0.40 14.13 105.6

2 5 MIXTARD ABT 66.66 0.33 -9.08 830.17 0.37 -5.69 87.27
3 1 AUGMENTIN GSK 77.03 0.38 1.07 826.07 0.37 2.32 94.68
4 4 GLYCOMET-GP USV 68.44 0.34 0.25 821.98 0.37 2.00 94.38
5 2 MONOCEF ATP 70.65 0.35 -0.35 663.75 0.30 8.48 100.38
6 6 LIV-52 HIM 65.55 0.33 6.89 647.94 0.29 16.69 107.97
7 7 PAN A.K 60.89 0.30 8.67 642.80 0.29 11.65 103.31
8 8 THYRONORM ABT 55.36 0.27 4.53 630.27 0.28 5.44 97.56
9 10 UDILIV SVY 54.07 0.27 17.27 608.38 0.27 25.23 115.87
10 11 CLAVAM A.K 53.59 0.27 2.24 608.05 0.27 -0.28 92.27
11 9 RYZODEG ABT 54.38 0.27 27.05 578.72 0.26 17.86 109.06
12 14 ZERODOL-SP IPC 51.65 0.26 12.40 576.62 0.26 18.23 109.4
13 12 PAN-D A.K 52.31 0.26 8.31 567.27 0.25 16.47 107.77
14 15 LANTUS S.A 44.60 0.22 4.10 562.76 0.25 -1.80 90.86
15 13 BETADINE WMC 51.70 0.26 6.58 557.11 0.25 2.20 94.56
16 22 DUOLIN CPL 40.36 0.20 14.58 526.06 0.23 12.15 103.77
17 19 MANFORCE MA& 42.42 0.21 7.64 512.27 0.23 9.43 101.26
18 43 ELECTRAL FC8 31.64 0.16 0.91 497.77 0.22 18.56 109.7
19 21 TELMA GMK 41.10 0.20 6.74 493.12 0.22 17.86 109.06
20 40 BUDECORT CPL 32.65 0.16 -0.20 480.65 0.21 12.08 103.7
21 18 ROSUVAS RBY 43.19 0.21 22.32 473.76 0.21 22.63 113.47
22 25 SHELCAL TNT 37.98 0.19 4.16 458.11 0.20 7.18 99.17
23 16 CALPOL GSK 43.93 0.22 -8.84 457.00 0.20 -4.75 88.13
24 17 DEXORANGE F-I 43.35 0.21 -5.15 456.99 0.20 -1.79 90.87
25 27 AZITHRAL AMB 36.45 0.18 -2.08 456.73 0.20 -1.00 91.61
26 24 ULTRACET JAN 38.07 0.19 4.87 427.95 0.19 5.57 97.68
27 20 DOLO MRB 41.88 0.21 6.03 424.85 0.19 -3.75 89.06
28 23 CILACAR JBH 39.70 0.20 20.14 421.72 0.19 18.83 109.95
29 31 ACILOC CI6 35.90 0.18 3.71 414.82 0.18 3.41 95.68
30 32 LEVIPIL SPI 35.64 0.18 2.83 414.53 0.18 9.93 101.71
31 34 ECOSPRIN-AV USV 34.59 0.17 9.49 404.23 0.18 9.92 101.7
32 30 MOXIKIND-CV MA& 35.95 0.18 5.40 393.99 0.18 8.13 100.05
33 51 DUPHASTON SVY 29.49 0.15 -15.42 387.08 0.17 4.25 96.46
34 26 PANTOP ATP 36.88 0.18 9.16 385.29 0.17 13.32 104.86
35 44 TELMA-H GMK 31.49 0.16 11.11 378.49 0.17 24.66 115.34
36 28 T-BACT GSK 36.25 0.18 9.88 371.75 0.17 -3.52 89.27
37 45 NOVOMIX ABT 31.20 0.15 -5.31 370.61 0.17 -13.16 80.36
38 33 PREVENAR-13 PFZ 34.69 0.17 45.21 369.95 0.16 25.15 115.8
39 29 MIKACIN ATP 36.08 0.18 7.21 361.26 0.16 3.45 95.72
40 47 RANTAC JBH 30.28 0.15 -8.60 359.43 0.16 1.72 94.12

Source: IQVIA TSA Dataset Aug'2024 5

Top Therapeutic Class and Indian
Vs MNC Trend - Aug’24
Month Aug'24 MAT Aug'24
Rank Rank
Therapy Growth Growth
MAT Month Value 'Cr MS% Value 'Cr MS%
% %
IPM 20164.0 100.0% 7.6% 224284.5 100.0% 8.1%
1 1 CARDIAC 2480.0 12.3% 11.3% 28392.0 12.7% 11.0%
2 2 ANTI-INFECTIVES 2439.3 12.1% 9.2% 25027.8 11.2% 6.0%
3 3 GASTRO INTESTINAL 2223.7 11.0% 8.9% 24020.8 10.7% 9.6%
4 4 ANTI DIABETIC 1727.3 8.6% 8.4% 19821.6 8.8% 7.1%
5 7 RESPIRATORY 1453.8 7.2% 3.1% 18009.3 8.0% 2.7%
6 5 PAIN / ANALGESICS 1650.1 8.2% 7.1% 17855.0 8.0% 8.0%
7 6 VITAMINS/MINERALS/NUTRIENTS 1610.2 8.0% 6.9% 17532.0 7.8% 8.2%
8 8 DERMA 1416.6 7.0% 8.7% 15469.8 6.9% 7.2%
9 9 NEURO / CNS 1179.7 5.9% 7.7% 13446.6 6.0% 8.6%
10 10 GYNAEC. 969.2 4.8% 1.6% 11103.7 5.0% 5.3%
11 11 ANTINEOPLAST/IMMUNOMODULATOR 491.1 2.4% 9.2% 5792.7 2.6% 20.3%
12 12 UROLOGY 438.3 2.2% 12.0% 4894.9 2.2% 13.3%
13 13 OPHTHAL / OTOLOGICALS 381.4 1.9% -9.9% 4289.9 1.9% 0.8%
14 14 HORMONES 301.0 1.5% 6.4% 3463.9 1.5% 6.2%
15 15 VACCINES 283.8 1.4% 9.6% 3278.7 1.5% 13.3%
16 16 HEPATOPROTECTIVES 264.3 1.3% 10.7% 2719.9 1.2% 16.0%
17 17 BLOOD RELATED 172.3 0.9% 2.5% 1993.9 0.9% 5.1%
18 18 STOMATOLOGICALS 161.4 0.8% 11.2% 1764.5 0.8% 9.1%
19 19 ANTIVIRAL 104.9 0.5% 2.9% 1191.2 0.5% 5.8%
20 21 PARENTERAL 59.2 0.3% 13.2% 680.4 0.3% 20.0%

• Monthly growth for Antineoplast/Immunomodulator, Opthal/Otological and

Parenteral was significantly lower then their respective MAT growth for Aug’24.
• Monthly growth for 13 among the Top 20 therapies was lower then their
respective MAT growth for Aug’24.

Indian_MNC Trend
200000 28%
21.4%
18.6%
20%
160000 14.2%
12.5%
17.6% 9.7% 10.0% 10.2% 10.8%
7.1% 14.3%7.8% 8.3% 12%
6.5%
120000
8.8% 9.8% 9.0%
7.7% 6.9% 4%
6.5% 5.7%
4.5% 4.2% 4.4%
80000
-4%
107,111

114,745

145,217

156,549

173,398

187,807

40000
19,513

58,942
91,638

97,607
20,387

21,708

22,941

53,579
10,852

11,312

66,288
12,421

73,062
13,536

30,365

31,699

34,129

36,477

-12%

0 -20%
MAT Aug'23
MAT Aug'21

MAT Aug'22

MAT Aug'23

MAT Aug'24

MAT Aug'21

MAT Aug'22

MAT Aug'24

MAT Aug'21

MAT Aug'22

MAT Aug'23

MAT Aug'24

ACUTE CHRONIC Overall

Indian MNC Indian Growth % MNC Growth %

Growth of MNC companies remained lower than Indian companies for both
Acute and Chronic segments but it is constantly catching up in both the
segments as shown in above chart.

Source: IQVIA TSA Dataset Aug'2024 6

Top NI in IPM last 12 months-
Aug’24
MAT
Rank BRANDS COMPANY SUPERGROUP
Aug'24'Cr

TOTAL NI VALUE 1322.2

1 PHENSEDYL ABBOTT* RESPIRATORY 45.5
2 ENHERTU ASTRAZENECA ANTINEOPLAST/IMMUNOMODULATOR 38.8
3 REJUNEX-CD3 NF INTAS * VITAMINS/MINERALS/NUTRIENTS 27.7
4 SYBRAVA LISY NOVARTIS* CARDIAC 21.0
5 VORXAR TORRENT * CARDIAC 20.3
6 LINVAS LUPIN CARDIAC 15.9
7 TYVALZI SUN* NEURO / CNS 13.5
8 EFFCM DRL GYNAEC. 13.0
9 GEMER SITA SUN* ANTI DIABETIC 12.5
10 RYBREVANT J&J ANTINEOPLAST/IMMUNOMODULATOR 10.5
11 HEXASIIL SERUM INST. VACCINES 10.5
12 MYORIL MAXX CORONA REM. PAIN / ANALGESICS 10.3
13 RESPIRA + GENO RESPIRATORY 10.2
14 VITCOFOL-FCM FDC GYNAEC. 10.1
15 RICHAR FCM ALEMBIC GYNAEC. 10.0
16 INSUQUICK USV ANTI DIABETIC 9.6
17 ALBUHIGH BDR PARENTERAL 9.4
18 LINARES-E ERIS LIFE.* ANTI DIABETIC 8.9
19 RANIDOM RAFT MANKIND GASTRO-INTESTINAL 8.8
20 GUFIPOL GUFIC ANTI-INFECTIVES 8.7

• 3349 brands were launched in last 12 months clocking a sale of 1322.2

Cr.
• Brands launched in last 12 months contributed 0.6% to IPM and 7.8%
to IPM growth for MAT Aug’24.
• Intas grossed the highest sales of 77.6 Cr from 41 brands, followed by
Abbott* @ 73.1 Cr with 42 brands and Sun*@ 72.1 Cr from 45 brands.
• Among the brands launched in last 12 months, Antidiabetic reported
the highest value of 154.1 Cr from 539 brands, followed by
Vitamins/Minerals/Nutrients with 150.2 Cr from 512 brands and
Gynaec. with a sale of 146.1 Cr from 201 brands.
• Highest number of brands were launched in Anti-Diabetic, Cardiac and
Vitamin/Minerals/Nutrients segment ranked in the same order.

Source: IQVIA TSA Dataset Aug'2024 7

Performance of Top 30 Metros in
IPM – Aug’24
MAT Aug'23 MAT Aug'24 MAT Aug'23 MAT Aug'24
Rank Metro Rank Metro
Values Growth Values Growth Values Growth Values Growth
Crores % Crores % Crores % Crores %

1 DELHI 9,313 20 % 10,341 11 % 17 KANPUR 1,103 7% 1,155 5%

2 MUMBAI 8,181 5% 8,492 4% 18 SURAT 1,120 15 % 1,154 3%

3 CALCUTTA 7,783 10 % 8,265 6% 19 KOCHI 1,076 15 % 1,154 7%

4 HYDERABAD 6,197 16 % 6,774 9% 20 LUDHIANA 1,079 10 % 1,148 6%

5 BANGALORE 4,986 19 % 5,319 7% 21 VIJAYWADA 1,004 12 % 1,086 8%

6 CHENNAI 4,311 8% 4,726 10 % 22 MADURAI 863 11 % 951 10 %

7 PUNE 2,700 20 % 3,027 12 % 23 BHOPAL 826 17 % 931 13 %

8 LUCKNOW 2,587 8% 2,857 10 % 24 NASIK 753 4% 881 17 %

9 AHMEDABAD 2,263 14 % 2,583 14 % 25 VADODARA 751 8% 760 1%

10 PATNA 1,967 16 % 2,024 3% 26 ALLAHABAD 687 9% 733 7%

11 JAIPUR 1,863 6% 1,941 4% 27 MEERUT 655 11 % 704 8%

12 AGRA 1,427 13 % 1,655 16 % 28 JABALPUR 661 5% 692 5%

13 VARANASI 1,458 5% 1,558 7% 29 VIZAG 613 6% 629 3%

14 COIMBATORE 1,229 15 % 1,368 11 % 30 ASANSOL 391 10 % 400 2%

15 NAGPUR 1,233 14 % 1,345 9% Grand Total 70,170 12.4 % 75,810 8.0 %

16 INDORE 1,090 19 % 1,156 6%

• Top 30 cities by market size mentioned in the above table grew slightly
slower @ 8% as compared to overall growth of 8.1% for MAT Aug’24.
• Top 30 metros in India contributed to 33.8% to IPM Sales for MAT
Aug’24, which is same as reported last month.
• Nashik , Agra, Ahmedabad, Bhopal and Pune were the fastest growing
markets among the Top 30 metros for MAT Aug’24 in the same order.
While the top 3 were the same last month also, Bhopal has overtaken
Pune to come at 4th spot.
• 12 out of Top 30 metros grew faster than IPM while 18 metros grew
equal to or slower than the IPM growth of 8.1% for MAT Aug’24.
• Among the 6 mega metros, Delhi remained the fastest growing @11%
for MAT Aug’24, followed by Chennai @9.6% and Hyderabad @9.3%.

Source: IQVIA TSA Dataset Aug'2024 8

Regional Performance in IPM-MAT
Aug’24
Zone State Values Crores MS % Growth %

North UTTAR PRADESH 25,233.4 41 % 8.8 %

DELHI 10,341.5 17 % 11.0 %
RAJASTHAN 9,033.9 15 % 3.9 %
PUNJAB 7,244.6 12 % 9.4 %
HARYANA 4,713.9 8% 8.7 %
JAMMU & KASHMIR 2,677.6 4% 9.2 %
UTTARAKHAND 1,630.2 3% 8.0 %
HIMACHAL PRADESH 681.5 1% 7.8 %
North Zone 61,556.6 27 % 8.5 %
South KARNATAKA 13,223.6 22 % 5.6 %
TAMILNADU 11,311.8 19 % 9.8 %
TELANGANA 11,251.7 19 % 9.6 %
KERALA 10,816.2 18 % 6.2 %
ANDHRA PRADESH 8,299.2 14 % 4.3 %
CHENNAI 4,725.8 8% 9.6 %
South Zone 59,628.2 27 % 7.4 %
East WEST BANGAL 14,294.2 26 % 9.1 %
BIHAR 11,794.5 21 % 7.2 %
KOLKATA 8,265.5 15 % 6.2 %
ASSAM 7,537.8 14 % 7.9 %
ORISSA 7,264.9 13 % 9.0 %
JHARKHAND 3,282.8 6% 10.1 %
CHATTISGARH 2,846.7 5% 11.2 %
East Zone 55,286.3 25 % 8.3 %
West MAHARASHTRA 19,278.0 40 % 9.2 %
MADHYA PRADESH 9,883.7 21 % 10.5 %
GUJARAT 9,519.8 20 % 8.3 %
MUMBAI 8,491.6 18 % 3.8 %
GOA 640.3 1% 6.5 %
West Zone 47,813.4 21 % 8.3 %
IPM 224,284.5 100 % 8.1 %

• Uttar Pradesh is the largest market in India contributing 11.3% to IPM

and 41% to North Zone followed by Maharashtra contributing 8.6% and
West Bengal contributing 6.4% to IPM.
• Chattisgarh is the fastest growing State growing by 11.2% followed by
Delhi growing at 11%, Madhya Pradesh at 10.5%, Jharkhand at 10.1%,
and Tamilnadu @ 9.8% for MAT Aug’24.

Source: IQVIA TSA Dataset Aug'2024 9

Zonal fastest growing among the
Top 50 companies- MAT Aug’24
Fastest Growing West Zone Fastest Growing South Zone
Rank
Corporation Values'Cr Growth % Corporation Values'Cr Growth %
1 ASTRAZENECA 210 36.1 % MERCK SPECIALITIES 308 38.5 %
2 LA RENON HEALTHCA. 390 19.7 % EAST WEST 281 29.2 %
3 UNISON 323 16.2 % LA RENON HEALTHCA. 489 25.4 %
4 PHARMED 175 15.4 % JANSSEN 334 22.8 %
5 SYSTOPIC 225 15.2 % ASTRAZENECA 255 20.1 %
6 RELIANCE LIFESCIE. 241 14.9 % IPCA LABS 1,028 16.8 %
7 TROIKAA 199 14.7 % GLENMARK 1,530 16.6 %
8 IPCA LABS 970 14.6 % CORONA REMEDIES 239 16.1 %
9 SAMARTH 204 13.9 % SAMARTH 253 14.5 %
10 MANKIND 2,320 12.3 % ICON LIFESCIENCES 213 12.8 %
11 CORONA REMEDIES 601 11.9 % INTAS * 1,836 12.6 %
12 ABBOTT* 2,970 11.6 % AJANTA 444 12.4 %
13 MACLEODS 1,551 11.4 % BHARAT SERUM 257 11.8 %
14 ERIS* 573 11.0 % SYSTOPIC 357 9.7 %
15 INTAS * 1,725 10.9 % FOURRTS 509 8.7 %
16 HETERO HEALTHCARE* 492 10.8 % CIPLA 3,290 8.7 %
17 JB * 478 10.7 % ERIS* 754 8.3 %
18 ARISTO * 1,090 10.1 % JB * 694 8.0 %
19 FDC 934 9.9 % SUN* 5,859 7.9 %
20 ZYDUS* 1,296 9.4 % ARISTO * 1,311 7.8 %

Fastest Growing North Zone Fastest Growing East Zone

Rank
Corporation Values'Cr Growth % Corporation Values'Cr Growth %
1 ASTRAZENECA 277 39.2 % CORONA REMEDIES 240 22.4 %
2 BAYER LTD. 171 32.5 % FOURRTS 204 17.9 %
3 SAMARTH 243 21.4 % LA RENON HEALTHCA. 364 17.7 %
4 MYLAN 232 18.7 % HETERO HEALTHCARE* 219 16.2 %
5 HETERO HEALTHCARE* 172 18.1 % FDC 291 13.1 %
6 MARTIN HARRIS 196 17.7 % MACLEODS 2,474 12.7 %
7 IPCA LABS 1,387 17.6 % SUN* 4,860 12.6 %
8 DRL 1,753 15.5 % JB * 638 11.8 %
9 HIMALAYA DRUG 686 14.0 % INTAS * 1,953 11.5 %
10 INTAS * 2,566 13.5 % GLENMARK 1,149 11.2 %
11 LA RENON HEALTHCA. 372 12.8 % TORRENT * 1,982 10.9 %
12 BHARAT SERUM 271 12.6 % IPCA LABS 1,166 10.3 %
13 BIOCON 186 12.1 % MANKIND 1,935 10.1 %
14 CORONA REMEDIES 293 11.8 % ABBOTT* 3,091 9.3 %
15 JB * 771 11.6 % SYSTOPIC 252 9.3 %
16 AJANTA 388 11.3 % ZYDUS* 1,555 9.2 %
17 EMCURE* 1,163 11.2 % EAST INDIA 172 9.1 %
18 GLENMARK 1,172 10.8 % MEYER ORGANICS 250 9.0 %
19 FDC 914 10.8 % LUPIN 2,107 8.7 %
20 JANSSEN 301 10.2 % BHARAT SERUM 178 8.6 %

Source: IQVIA TSA Dataset Aug'2024

10
Zonal fastest growing among the
Top 51-100 companies- MAT
Aug’24
Fastest Growing West Zone Fastest Growing South Zone
Rank
Corporation Values'Cr Growth % Corporation Values'Cr Growth %
1 NATCO 107 38.4 % MSN LABS 103 75.1 %
2 MSN LABS 107 35.5 % BRISTOL-MYER SQUIB 64 65.8 %
3 CELON LAB 75 31.5 % KEPLER HEALTHCARE 76 44.0 %
4 BDF 115 28.1 % FRESENIUS KABI 175 36.6 %
5 GALDERMA 110 27.5 % BRINTON 83 25.8 %
6 ICON LIFESCIENCES 69 21.8 % NUTRICIA INTERNAT 137 23.9 %
7 KHANDELWAL 74 19.0 % MARTIN HARRIS 74 21.4 %
8 BIOLOGICAL E 82 18.6 % BAYER LTD. 101 20.9 %
9 NEON LABS 135 15.6 % TROIKAA 142 20.1 %
10 BAYER LTD. 91 15.3 % NATCO 137 19.9 %
11 NUTRICIA INTERNAT 151 13.7 % RPG LIFE SCIENCES 149 18.4 %
12 SERVIER INDIA 125 13.4 % LINUX LAB 140 18.1 %
13 PIRAMALHEALTHCARE* 86 12.7 % ENTOD 136 16.6 %
14 KLM LABS 103 12.4 % JUGGAT 111 15.7 %
15 LINCOLN 116 12.3 % MYLAN 164 13.2 %
16 SERUM INSTITUTE 117 12.2 % KLM LABS 144 12.2 %
17 MERCK SPECIALITIES 120 12.1 % NEON LABS 182 12.0 %
18 UNIMED TECHNOLOGIE 68 12.0 % PIRAMALHEALTHCARE* 72 11.8 %
19 RAPTAKOS BRETT 150 11.5 % UNIMED TECHNOLOGIE 153 11.6 %
20 MYLAN 133 11.1 % BAYER ZYDUS 145 11.3 %

Fastest Growing North Zone Fastest Growing East Zone

Rank
Corporation Values'Cr Growth % Corporation Values'Cr Growth %
1 TAKEDA 88 120.9 % NUTRICIA INTERNAT 143 32.8 %
2 ELI LILLY 117 68.9 % GALDERMA 70 27.7 %
3 NATCO 141 50.6 % ALTEUS BIOGENICS 111 25.9 %
4 MSN LABS 151 31.3 % MERCK SPECIALITIES 131 24.7 %
5 MERCK SPECIALITIES 104 28.9 % NEON LABS 99 24.2 %
6 NUTRICIA INTERNAT 158 26.9 % ASTRAZENECA 107 24.0 %
7 ALCON 69 26.7 % MYLAN 76 22.4 %
8 TROIKAA 167 24.5 % TROIKAA 74 19.4 %
9 KHANDELWAL 114 22.5 % UNIMED TECHNOLOGIE 78 18.8 %
10 AAREEN HEALTHCARE 152 21.3 % NATCO 153 18.7 %
11 PIRAMALHEALTHCARE* 90 20.9 % SERVIER INDIA 97 15.8 %
12 MOREPEN LABS 74 20.5 % AGLOWMED 97 14.9 %
13 OVERSEAS 131 20.0 % OZONE 106 13.8 %
14 RPG LIFE SCIENCES 141 18.4 % RPG LIFE SCIENCES 80 13.7 %
15 GALDERMA 84 18.0 % TABLETS INDIA 157 13.6 %
16 TAS MED 82 17.3 % BAYER ZYDUS 73 12.5 %
17 UNIMED TECHNOLOGIE 89 15.1 % ICPA HEALTH 82 10.8 %
18 EAST INDIA 96 13.8 % RELIANCE LIFESCIE. 103 10.7 %
19 SERVIER INDIA 120 13.7 % MARTIN HARRIS 149 9.8 %
20 AKUMENTIS HEALTH 126 12.9 % CAPLET INDIA 67 9.7 %

Source: IQVIA TSA Dataset Aug'2024 11

East Zone Top Companies- MAT
Aug’24
ASSAM Bihar
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 ABBOTT* 512.9 11 % ALKEM* 1,177.1 6%
2 ALKEM* 489.8 6% ARISTO * 1,159.3 4%
3 SUN* 486.9 13 % MACLEODS 850.9 19 %
4 ALEMBIC 462.0 7% SUN* 719.5 16 %
5 LUPIN 414.1 6% ABBOTT* 610.3 9%
6 EMCURE* 271.5 2% CIPLA 425.5 11 %
7 INTAS * 262.5 17 % LUPIN 375.7 11 %
8 CIPLA 262.3 5% INTAS * 370.3 9%
9 DRL 235.8 13 % MANKIND 367.2 11 %
10 GSK* 213.0 7% ZYDUS* 293.0 8%
11 ZYDUS* 196.3 15 % GSK* 262.9 1%
12 MACLEODS 195.9 6% MICRO* 254.5 8%
13 GLENMARK 179.6 11 % ALEMBIC 245.1 8%
14 TORRENT * 176.7 11 % TORRENT * 244.3 17 %
15 MANKIND 176.1 5% IPCA LABS 226.0 12 %
16 IPCA LABS 148.1 4% DRL 214.6 -9 %
17 PFIZER* 130.2 17 % PFIZER* 179.4 1%
18 ARISTO * 119.4 2% EMCURE* 174.8 -2 %
19 LA RENON 111.4 20 % CADILA 159.2 -4 %
20 USV 96.7 2% FRANCO INDIAN 157.8 -19 %
Chattisgarh Jharkhand
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 MANKIND 212.3 14 % ALKEM* 241.7 7%
2 SUN* 180.6 14 % ABBOTT* 214.4 11 %
3 ABBOTT* 172.2 3% MACLEODS 205.7 9%
4 MACLEODS 132.3 9% ARISTO * 174.6 7%
5 LUPIN 106.8 16 % MANKIND 155.6 11 %
6 DRL 99.8 21 % SUN* 154.8 16 %
7 ZYDUS* 92.4 4% LUPIN 131.0 16 %
8 CIPLA 80.4 3% CIPLA 128.7 11 %
9 ARISTO * 79.1 15 % DRL 119.0 18 %
10 ALKEM* 70.9 16 % IPCA LABS 109.7 14 %
11 INTAS * 67.4 10 % TORRENT * 95.3 1%
12 GSK* 67.3 5% GSK* 70.8 7%
13 TORRENT * 62.1 3% INTAS * 64.9 10 %
14 IPCA LABS 57.2 15 % ALEMBIC 62.2 7%
15 FDC 46.7 1% USV 58.0 15 %
16 EMCURE* 44.0 6% ZYDUS* 48.7 9%
17 ERIS* 43.6 8% GLENMARK 48.0 14 %
18 GLENMARK 42.2 48 % PFIZER* 47.0 13 %
19 USV 42.0 15 % EMCURE* 46.8 6%
20 PFIZER* 39.7 9% MICRO* 43.8 9%
Orissa West Bengal Kolkata
Rank Company Value'Cr Growth % Company Value'Cr Growth % Company Value'Cr Growth %
1 MACLEODS 463.7 15 % SUN* 2,218.7 16 % SUN* 755.8 3%
2 MANKIND 435.5 8% ALKEM* 1,036.1 7% TORRENT * 590.1 11 %
3 ABBOTT* 435.5 13 % ABBOTT* 787.6 10 % INTAS * 424.6 12 %
4 ALKEM* 404.9 7% CIPLA 585.8 6% LUPIN 413.3 0%
5 INTAS * 348.0 11 % TORRENT * 566.9 17 % DRL 398.4 4%
6 SUN* 343.9 6% LUPIN 499.5 13 % ALKEM* 366.1 3%
7 ARISTO * 285.6 8% ZYDUS* 489.8 7% ABBOTT* 358.2 5%
8 TORRENT * 247.0 -1 % GSK* 472.5 4% CIPLA 266.9 -0 %
9 CIPLA 244.3 14 % INTAS * 415.8 11 % MACLEODS 243.2 8%
10 ZYDUS* 224.3 22 % DRL 405.3 10 % EMCURE* 230.4 10 %
11 DRL 192.4 9% MACLEODS 382.8 8% GLENMARK 219.0 1%
12 GLENMARK 180.1 15 % MANKIND 376.3 12 % IPCA LABS 212.9 12 %
13 IPCA LABS 175.0 13 % GLENMARK 334.9 13 % MANKIND 212.4 10 %
14 LUPIN 166.6 10 % ARISTO * 313.3 6% ZYDUS* 210.4 4%
15 U S V 151.2 9% ALEMBIC 280.2 5% JB * 197.2 13 %
16 ALEMBIC 150.8 4% EMCURE* 277.1 1% PFIZER* 183.7 -2 %
17 EMCURE* 136.8 5% IPCA LABS 237.1 6% SANOFI* 150.6 15 %
18 MICRO* 100.6 12 % JB * 193.6 8% USV 136.0 3%
19 AJANTA 90.8 13 % WALLACE* 168.9 7% GSK* 135.5 -1 %
20 ERIS* 85.3 -1 % USV 156.2 6% AJANTA 107.7 5%

Source: IQVIA TSA Dataset Aug'2024 12

 East Zone Top Brands- MAT Aug’24
Assam Bihar
Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %
1 PAN ALKEM* 56.1 11 % MONOCEF ARISTO* 104.0 3%
2 LIV-52 HIMALAYA 41.9 10 % CLAVAM ALKEM* 94.0 -1 %
3 UDILIV ABBOTT* 37.6 20 % MONTAZ ARISTO* 80.5 7%
4 PAN-D ALKEM* 35.9 12 % XONE ALKEM* 72.5 1%
5 TELLZY-AM ALEMBIC 35.1 24 % ACILOC CADILA 67.0 -11 %
6 AZITHRAL ALEMBIC 33.8 1% ELECTRAL FDC 64.4 28 %
7 CLAVAM ALKEM* 33.6 -9 % DEXORANGE FRANCO 63.8 -4 %
8 THYRONORM ABBOTT* 32.9 22 % AZITHRAL ALEMBIC 62.7 9%
9 ELECTRAL FDC 29.6 4% PANTOP-D ARISTO* 61.1 -13 %
10 RYZODEG ABBOTT* 28.6 33 % MONOCEF-SB ARISTO* 60.8 4%
11 MIXTARD ABBOTT* 28.3 -1 % MIKACIN ARISTO* 58.0 -1 %
12 TELLZY ALEMBIC 26.1 14 % ZERODOL-SP IPCA 52.9 4%
13 BEVON EMCURE* 25.9 2% PAN ALKEM* 52.2 26 %
14 RABLET-D LUPIN 25.5 13 % A TO Z NS ALKEM* 51.4 -4 %
15 BETNOVATE-N GSK* 22.4 87 % LIV-52 HIMALAYA 48.9 7%
16 BETADINE WIN MEDI. 22.1 -2 % TRAXOL ALKEM* 48.8 9%
17 GLYCOMET-GP USV 21.3 -0 % TRAXOL-S ALKEM* 47.3 14 %
18 T-BACT GSK* 20.9 6% TAXIM-O ALKEM* 44.7 3%
19 NOVOMIX ABBOTT* 20.9 -0 % ODICEF GALPHA 44.1 1%
20 ABHAYRAB INDIAN IMMUN.. 20.1 70 % PANTOP ARISTO* 43.1 11 %
Chattisgarh Jharkhand
Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %
1 MANFORCE MANKIND 31.1 4% RYZODEG ABBOTT* 20.9 49 %
2 AMLOKIND-AT MANKIND 11.4 24 % BETADINE WIN MEDI. 19.6 1%
3 BETADINE WIN MEDI. 11.3 11 % ELECTRAL FDC 18.3 19 %
4 ELECTRAL FDC 10.5 24 % CLAVAM ALKEM* 17.9 -4 %
5 RYZODEG ABBOTT* 10.3 5% MIXTARD ABBOTT* 17.5 -2 %
6 ACILOC CADILA 10.0 20 % RAPITHER-AB IPCA 16.6 26 %
7 GLYCOMET-GP USV 9.8 8% MANFORCE MANKIND 16.5 4%
8 MONOCEF ARISTO* 9.8 28 % XONE ALKEM* 16.5 -1 %
9 BETNOVATE-C GSK* 9.8 -12 % ALBUREL RELIANCE LIFE. 16.5 2%
10 MOXIKIND-CV MANKIND 8.8 25 % ZERODOL-SP IPCA 15.6 9%
11 ZERODOL-SP IPCA 8.7 19 % AZITHRAL ALEMBIC 13.5 7%
12 ZINCOVIT APEX 8.7 6% ACILOC CADILA 13.3 49 %
13 DEXORANGE FRANCO 8.3 -5 % TAXIM-O ALKEM* 13.1 -7 %
14 DEXOLAC NUTRICIA 8.2 99 % UDILIV ABBOTT* 13.0 23 %
15 LIV-52 HIMALAYA 8.0 11 % DEXOLAC NUTRICIA 13.0 116 %
16 MIXTARD ABBOTT* 8.0 -10 % PAN ALKEM* 12.2 11 %
17 PANDERM ++ MACLEODS 7.9 -6 % CRESP DRL 12.1 60 %
18 LEVIPIL SUN* 7.8 19 % THYROX MACLEODS 11.7 9%
19 AZITHRAL ALEMBIC 7.7 14 % XONE-XP ALKEM* 11.5 13 %
20 ZIFI FDC 7.4 2% MIKACIN ARISTO* 11.3 -1 %
Orissa West Bengal Kolkata
Rank Growth Growth Growth
Brand Company Value'Cr Brand Company Value'Cr Brand Company Value'Cr
% % %
1 MIXTARD ABBOTT* 46.0 6 % PAN-D ALKEM* 130.0 16 % SHELCAL TORRENT * 56.1 66 %
2 LACTODEX RAPTAKOS 45.1 15 % PAN ALKEM* 110.1 5% PAN-D ALKEM* 55.5 16 %
3 GLYCOMET-GP U S V 44.6 10 % CLAVAM ALKEM* 105.9 -3 % PAN ALKEM* 53.0 6%
4 MANFORCE MANKIND 37.1 5 % AUGMENTIN GSK* 82.7 7% CILACAR JB * 43.2 24 %
5 CLAVAM ALKEM* 32.2 -4 % MOXCLAV SUN* 80.2 16 % TELMA GLENMARK 39.7 4%
6 PAN ALKEM* 31.2 13 % CALPOL GSK* 74.7 -8 % LANTUS SANOFI* 39.6 16 %
7 UDILIV ABBOTT* 26.3 40 % AZITHRAL ALEMBIC 73.4 -6 % OMEZ DRL 38.8 12 %
8 ASCORIL-LS GLENMARK 24.5 16 % T-BACT GSK* 64.4 1% JANUMET MSD* 36.6 28 %
9 PANTOP-D ARISTO* 23.7 -11 % FORACORT CIPLA 63.4 14 % RANTAC JB * 36.3 -12 %
10 ZERODOL-SP IPCA 23.6 0 % RANTAC JB * 57.3 -1 % CILACAR-T JB * 34.1 38 %
11 CHERI ALKEM* 22.5 23 % PANTOCID-D SUN* 52.7 17 % CHYMORAL TORRENT * 33.2 74 %
12 AZITHRAL ALEMBIC 20.1 -4 % DUOLIN CIPLA 47.4 6% NEXPRO-RD TORRENT * 31.1 73 %
13 PAN-D ALKEM* 19.5 13 % ROSUVAS SUN* 46.7 39 % ZERODOL-SP IPCA 30.6 34 %
14 CYRA-D SYSTOPIC 18.5 -10 % VOLINI SUN* 44.3 0% RYZODEG ABBOTT* 29.2 7%
15 PANTOP ARISTO* 18.4 10 % TELMA GLENMARK 42.9 21 % MIXTARD ABBOTT* 27.3 14 %
16 FORACORT CIPLA 17.9 10 % UDILIV ABBOTT* 42.3 21 % CRESP DRL 27.0 30 %
17 THYROX MACLEODS 17.8 18 % SPORIDEX SUN* 41.7 14 % BETADINE WIN MEDI. 26.3 -10 %
18 UNWANTED-KIT MANKIND 17.7 2 % ELTROXIN GSK* 40.9 11 % ROSUVAS SUN* 23.2 -2 %
19 MONTEK-LC SUN* 17.2 10 % ASCORIL-LS GLENMARK 39.9 5% CLAVAM ALKEM* 22.8 -7 %
20 O2 MEDLEY 16.4 -8 % A TO Z NS ALKEM* 39.3 19 % FORACORT CIPLA 22.5 12 %

Source: IQVIA TSA Dataset Aug'2024 13

North Zone Top Companies- MAT
Aug’24
Delhi Haryana
Rank
Company Value'Cr Growth % Company Value'Cr Growth %
1 SUN* 968.1 13 % CIPLA 546.9 5%
2 ABBOTT* 754.1 17 % ABBOTT* 362.0 11 %
3 INTAS * 684.3 24 % SUN* 334.8 7%
4 CIPLA 611.8 9% INTAS * 256.1 26 %
5 DRL 416.1 8% LUPIN 225.8 9%
6 LUPIN 355.8 8% MANKIND 192.7 15 %
7 TORRENT * 331.9 12 % ZYDUS* 166.7 8%
8 GSK* 288.3 8% GSK* 126.5 -1 %
9 MANKIND 279.1 13 % TORRENT * 124.6 1%
10 EMCURE* 269.0 19 % DRL 120.0 27 %
11 ZYDUS* 254.7 -6 % MACLEODS 114.2 2%
12 ALKEM* 253.7 -2 % GLENMARK 101.0 12 %
13 PFIZER* 246.2 9% USV 97.4 9%
14 GLENMARK 224.2 8% ALKEM* 90.4 7%
15 JANSSEN 198.1 13 % IPCA LABS 89.0 16 %
16 USV 179.5 5% ARISTO * 79.6 7%
17 MACLEODS 155.1 8% SANOFI* 73.7 9%
18 ASTRAZENECA 143.6 41 % MICRO* 72.2 4%
19 IPCA LABS 143.4 9% EMCURE* 70.4 11 %
20 MICRO* 137.0 -3 % PFIZER* 63.9 -0 %
Himachal Pradesh J&K Punjab
Rank Growth Growth Growth
Company Value'Cr Company Value'Cr Company Value'Cr
% % %
1 CIPLA 67.4 2% SUN* 207.8 10 % CIPLA 745.8 10 %
2 MACLEODS 32.2 15 % INTAS * 198.7 6% SUN* 522.7 8%
3 ABBOTT* 31.2 12 % CIPLA 171.2 13 % ABBOTT* 521.6 13 %
4 INTAS * 29.0 3% ABBOTT* 156.6 7% MICRO* 265.6 2%
5 ZYDUS* 28.3 23 % LUPIN 140.4 18 % LUPIN 249.5 5%
6 IPCA LABS 27.7 7% ARISTO * 115.2 5% INTAS * 245.9 14 %
7 SUN* 27.3 -5 % MACLEODS 89.9 3% GSK* 237.2 3%
8 USV 26.3 4% DRL 86.0 17 % ZYDUS* 219.7 11 %
9 LUPIN 24.9 13 % ERIS* 85.3 26 % MANKIND 212.9 5%
10 MANKIND 24.2 12 % ZYDUS* 77.3 3% MACLEODS 211.7 3%
11 ARISTO * 23.7 16 % IPCA LABS 74.0 -0 % TORRENT * 198.7 13 %
12 EMCURE* 19.4 5% TORRENT * 67.9 -0 % DRL 193.7 14 %
13 GSK* 19.3 9% GSK* 66.3 3% GLENMARK 171.3 15 %
14 GLENMARK 16.2 6% ALEMBIC 60.8 3% IPCA LABS 142.8 23 %
15 TORRENT * 13.1 29 % GLENMARK 59.3 3% USV 141.4 14 %
16 BDF 11.5 -37 % EMCURE* 57.2 4% PFIZER* 134.4 9%
17 PFIZER* 10.6 16 % MANKIND 53.8 2% AAREEN HEALTHCARE 120.8 20 %
18 HIMALAYA DRUG 8.8 13 % ALKEM* 45.7 -1 % EMCURE* 113.7 18 %
19 DABUR INDIA 8.6 -7 % PFIZER* 38.1 3% ARISTO * 111.2 4%
20 DRL 8.5 -17 % MICRO* 37.1 5% ALKEM* 106.8 9%
Rajasthan Uttar Pradesh Uttarakhand
Rank Growth Growth Growth
Company Value'Cr Company Value'Cr Company Value'Cr
% % %
1 SUN* 753.8 4% MANKIND 2,271.0 7% MANKIND 101.1 9%
2 CIPLA 584.5 6% CIPLA 1,519.5 12 % MACLEODS 93.9 9%
3 MACLEODS 496.7 2% ABBOTT* 1,459.7 7% CIPLA 87.3 1%
4 ABBOTT* 478.0 4% SUN* 1,168.3 10 % ABBOTT* 85.5 9%
5 INTAS * 398.1 6% ALKEM* 1,124.3 6% SUN* 76.7 -4 %
6 ALKEM* 348.5 6% MACLEODS 1,042.7 11 % LUPIN 75.2 12 %
7 MANKIND 344.6 5% ARISTO * 1,038.5 9% MICRO* 62.4 2%
8 TORRENT * 336.3 7% LUPIN 857.8 9% INTAS * 59.1 13 %
9 ARISTO * 327.4 7% ZYDUS* 714.5 7% GSK* 55.7 -4 %
10 ZYDUS* 299.3 3% GSK* 710.5 -1 % GLENMARK 54.1 15 %
11 LUPIN 279.4 4% INTAS * 694.8 8% ARISTO * 50.9 6%
12 DRL 238.6 10 % TORRENT * 681.3 9% DRL 49.3 23 %
13 GSK* 206.3 5% IPCA LABS 662.0 23 % ALKEM* 46.7 2%
14 IPCA LABS 204.1 12 % DRL 641.0 22 % IPCA LABS 43.9 25 %
15 EMCURE* 143.1 6% FDC 554.1 14 % TORRENT * 43.8 -6 %
16 GLENMARK 133.0 2% MICRO* 495.9 2% ERIS* 33.3 3%
17 MICRO* 127.0 -4 % EMCURE* 471.8 9% HIMALAYA DRUG 31.8 9%
18 JB * 122.8 9% GLENMARK 413.1 15 % ZYDUS* 27.9 4%
19 FDC 107.6 7% JB * 383.6 17 % SANOFI* 22.7 15 %
20 PFIZER* 105.5 -2 % PFIZER* 377.0 -11 % PFIZER* 20.5 11 %

Source: IQVIA TSA Dataset Aug'2024 14

North Zone Top Brands- MAT
Aug’24
Delhi Haryana Himachal Pradesh
Rank Value Growth Value' Growth Value' Growth
Brand Company Brand Company Brand Company
'Cr % Cr % Cr %
1 ULTRACET JANSSEN 79.0 1% FORACORT CIPLA 37.1 11 % HANSAPLAST BDF 11.5 -37 %
2 AUGMENTIN GSK* 71.9 14 % LIV-52 HIMALAYA 31.1 29 % NEW SARIDON BAYER 6.2 0%
3 LIV-52 HIMALAYA 60.0 44 % AUGMENTIN GSK* 24.7 -10 % METPURE-XL EMCURE* 5.0 -3 %
4 VOLINI SUN* 59.8 -0 % UDILIV ABBOTT* 23.3 31 % BECOSULES PFIZER* 4.5 25 %
5 REVITAL H SUN* 58.7 13 % RYZODEG ABBOTT* 20.4 20 % FORACORT CIPLA 4.2 16 %
6 UDILIV ABBOTT* 58.5 25 % MANFORCE MANKIND 18.3 11 % LIV-52 HIMALAYA 4.0 22 %
7 REMICADE JANSSEN 56.6 32 % GLYCOMET-GP USV 17.4 -5 % THYROX MACLEODS 3.9 28 %
8 RYBELSUS ABBOTT* 50.4 94 % GLUCONORM-G LUPIN 17.2 16 % GLYCOMET-GP U S V 3.6 4%
9 JARDIANCE BOEHRING. 50.0 26 % DUOLIN CIPLA 17.0 11 % MANFORCE MANKIND 3.5 24 %
10 PREVENAR-13 PFIZER* 49.5 23 % RYBELSUS ABBOTT* 16.8 87 % URIMAX-D CIPLA 3.3 25 %
11 THYRONORM ABBOTT* 48.8 12 % LANTUS SANOFI* 16.7 23 % ROSUVAS SUN* 2.8 58 %
12 ZAVICEFTA PFIZER* 48.5 327 % BUDECORT CIPLA 16.6 -5 % AUGMENTIN GSK* 2.8 -12 %
13 ROSUVAS SUN* 44.8 78 % MONTAIR-LC CIPLA 15.7 4% ZERODOL-SP IPCA 2.8 6%
14 LEVERA INTAS * 41.9 50 % BETADINE WIN MEDI. 14.6 -7 % DUOLIN CIPLA 2.8 -1 %
15 FORACORT CIPLA 41.3 14 % ROSUVAS SUN* 12.7 12 % CETAPHIL GALDERMA 2.7 120 %
16 CYRAMZA ELI LILLY 40.5 28 % FOLISURGE INTAS * 12.6 30 % JALRA-M USV 2.5 -21 %
17 TAGRISSO ASTRA 36.6 78 % MONOCEF ARISTO* 12.6 1% BRYXTA ZYDUS* 2.4 63 %
18 RYZODEG ABBOTT* 36.2 18 % ZIFI FDC 12.4 -7 % AMOXYCLAV ABBOTT* 2.4 81 %
19 GABAPIN NT INTAS * 35.5 60 % ENCLEX CIPLA 12.3 14 % BETADINE WIN MEDI. 2.3 19 %
20 BETADINE WIN MEDI. 33.8 -10 % AEROCORT CIPLA 12.0 34 % FLAVEDON SERVIER 2.3 1%
J&K Punjab Rajasthan
Rank Value' Growth Value' Growth Value' Growth
Brand Company Brand Company Brand Company
Cr % Cr % Cr %
1 NEW SARIDON BAYER 28.0 >500% LIV-52 HIMALAYA 47.3 33 % MONOCEF ARISTO* 68.6 6%
2 HUMINSULIN LUPIN 17.0 7% UDILIV ABBOTT* 45.1 24 % FORACORT CIPLA 55.9 14 %
3 UDILIV ABBOTT* 16.9 29 % FORACORT CIPLA 40.0 6% MANFORCE MANKIND 39.4 14 %
4 PANTOP ARISTO* 16.0 5% AUGMENTIN GSK* 36.0 -5 % AUGMENTIN GSK* 35.9 4%
5 AUGMENTIN GSK* 14.8 -6 % FLEXBUMIN TAKEDA 34.9 >500% AMICIN ZYDUS* 28.7 11 %
6 THYRONORM ABBOTT* 14.6 8% SUPRADYN BAYER 30.3 3% BETNOVATE-N GSK* 25.4 6%
7 MONOCEF-SB ARISTO* 12.4 14 % BUDECORT CIPLA 28.7 17 % LIV-52 HIMALAYA 25.4 5%
8 PANTOP-D ARISTO* 12.1 -0 % DYTOR CIPLA 27.8 22 % LANTUS SANOFI* 24.9 6%
9 DART OLD JUGGAT 9.3 21 % MYHEP ALL MYLAN 27.5 -23 % LEVIPIL SUN* 24.6 25 %
10 TELMA-AM GLENMARK 9.1 21 % BECOZYM-C FORT BAYER 25.8 1% ZERODOL-SP IPCA 23.1 25 %
11 GLUCONORM-G LUPIN 8.7 32 % ELORES CIPLA 24.8 64 % RYZODEG ABBOTT* 22.9 21 %
12 ZERODOL-SP IPCA 8.6 9% SOFOCURE EMCURE 24.5 65 % DEXORANGE FRANCO 22.9 -14 %
13 INFLUVAC ABBOTT* 8.5 -14 % BECOSULES PFIZER* 24.5 14 % DUOLIN CIPLA 22.8 9%
14 MONOCEF ARISTO* 8.4 -4 % ACILOC CADILA 23.8 15 % MONTAIR-LC CIPLA 21.9 -7 %
15 LIV-52 HIMALAYA 8.2 26 % GLYCOMET-GP USV 23.4 3% RANTAC JB * 21.1 11 %
16 CYRA-D SYSTOPIC 8.2 13 % ECOSPRIN-AV USV 22.9 13 % PANTOCID-D SUN* 20.9 -3 %
17 MANFORCE MANKIND 8.2 12 % MONTAIR-LC CIPLA 22.4 -3 % THYRONORM ABBOTT* 20.6 1%
18 URISPAS MARTIN H. 8.1 2% MIXTARD ABBOTT* 22.2 -8 % MONOCEF-SB ARISTO* 20.4 5%
19 ROSUVAS SUN* 7.8 -0 % INFANRIX HEXA GSK* 21.6 13 % GEMER SUN* 20.2 -1 %
20 BUDAMATE LUPIN 7.7 46 % MANFORCE MANKIND 21.3 5% CREMAFFIN PLUS ABBOTT* 20.2 27 %

Uttar Pradesh Uttarakhand

Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %
1 MONOCEF ARISTO* 186.2 10 % LIV-52 HIMALAYA 14.2 12 %
2 UNWANTED-KIT MANKIND 151.0 3% AUGMENTIN GSK* 11.4 -6 %
3 LIV-52 HIMALAYA 149.7 18 % MANFORCE MANKIND 8.9 7%
4 MANFORCE MANKIND 135.2 11 % BETADINE WIN MEDI. 8.4 -5 %
5 ACILOC CADILA 131.4 5% FORACORT CIPLA 7.5 21 %
6 ZIFI FDC 115.9 5% ACILOC CADILA 5.9 4%
7 ELECTRAL FDC 111.0 36 % DOLO MICRO* 5.5 -14 %
8 FORACORT CIPLA 110.7 9% LEVERA INTAS * 5.3 12 %
9 MOXIKIND-CV MANKIND 106.6 12 % LANTUS SANOFI* 5.1 12 %
10 AUGMENTIN GSK* 103.3 -0 % JOHNSON BABY J&J 5.0 58 %
11 ZERODOL-SP IPCA 102.2 24 % HEPA-MERZ WIN MEDI. 4.9 28 %
12 DEXORANGE FRANCO 98.7 -7 % JANUMET MSD* 4.8 3%
13 MIKACIN ARISTO* 96.1 8% MONOCEF ARISTO* 4.8 -5 %
14 BETADINE WIN MEDI. 95.2 12 % THYRONORM ABBOTT* 4.7 8%
15 CALPOL GSK* 90.5 -3 % CANDID GLENMARK 4.7 76 %
16 METROGYL JB * 80.2 10 % CALPOL GSK* 4.6 -11 %
17 GUDCEF MANKIND 75.3 12 % BETNOVATE-N GSK* 4.6 -12 %
18 UDILIV ABBOTT* 73.0 27 % TELMA-AM GLENMARK 4.5 12 %
19 DUOLIN CIPLA 72.0 24 % TELMA GLENMARK 4.4 18 %
20 BETNOVATE-N GSK* 67.4 -12 % GLIMISAVE MV ERIS* 4.4 7%

Source: IQVIA TSA Dataset Aug'2024 15

West Zone Top Companies- MAT
Aug’24
Goa Gujarat
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 SUN* 52.7 9% ABBOTT* 629.0 10 %
2 ABBOTT* 38.9 3% CIPLA 619.9 5%
3 CIPLA 29.5 -6 % SUN* 499.0 11 %
4 ZYDUS* 29.3 -9 % TORRENT * 491.2 7%
5 GSK* 28.6 29 % ZYDUS* 404.2 15 %
6 EMCURE* 23.0 6% INTAS * 343.0 2%
7 LUPIN 22.1 5% MANKIND 342.0 6%
8 TORRENT * 16.4 18 % UNISON 318.5 16 %
9 MANKIND 16.0 -14 % DRL 243.0 14 %
10 ARISTO * 15.8 10 % CORONA REMEDIES 210.3 11 %
11 MACLEODS 15.1 6% EMCURE* 208.4 7%
12 DRL 14.4 11 % LUPIN 200.1 9%
13 GLENMARK 14.2 16 % GSK* 194.7 0%
14 MICRO* 14.0 44 % IPCA LABS 188.6 10 %
15 FRANCO INDIAN 12.7 49 % ARISTO * 184.9 17 %
16 ALEMBIC 12.1 -9 % ALKEM* 184.2 3%
17 INDOCO* 12.1 -17 % USV 182.4 -3 %
18 USV 11.7 -2 % MACLEODS 177.6 10 %
19 PIRAMALHEALTHCARE* 11.3 161 % JB * 140.2 14 %
20 ERIS* 10.8 6% PFIZER* 132.4 16 %

Madhya Pradesh Maharashtra Mumbai

Growth Growth Growth
Rank Company Value'Cr Company Value'Cr Company Value'Cr
% % %
1 MANKIND 609.3 12 % CIPLA 1,125.8 5% ABBOTT* 711.5 18 %

2 ABBOTT* 571.6 13 % SUN* 1,070.0 14 % SUN* 579.8 0%

3 ARISTO * 509.6 9% ABBOTT* 1,018.9 8% CIPLA 486.8 -6 %

4 SUN* 495.6 9% MANKIND 982.7 13 % TORRENT * 447.3 7%

5 MACLEODS 451.3 13 % EMCURE* 851.3 9% INTAS * 419.9 6%

6 LUPIN 370.6 15 % MACLEODS 698.9 13 % MANKIND 370.4 19 %

7 ALKEM* 358.0 10 % ALKEM* 697.3 8% EMCURE* 344.4 1%

8 CIPLA 350.3 13 % DRL 651.4 13 % DRL 336.9 -1 %

9 INTAS * 340.1 16 % INTAS * 613.3 18 % USV 252.4 7%

10 ZYDUS* 289.6 8% FDC 551.0 12 % LUPIN 225.2 9%

11 DRL 226.1 11 % LUPIN 530.3 5% GLENMARK 224.1 1%

12 GSK* 201.5 4% TORRENT * 480.6 9% ALKEM* 222.1 1%

13 FDC 201.0 11 % ZYDUS* 436.9 10 % GSK* 214.0 -13 %

14 TORRENT * 188.0 19 % IPCA LABS 417.2 12 % MACLEODS 207.6 6%

15 IPCA LABS 177.3 20 % GLENMARK 380.4 16 % IPCA LABS 182.1 21 %

16 EMCURE* 160.0 2% USV 371.4 4% PFIZER* 175.7 -5 %

17 U S V 149.5 12 % GSK* 367.1 6% ZYDUS* 135.9 0%

18 ALEMBIC 144.9 8% ARISTO * 322.5 10 % SANOFI* 119.0 -8 %

19 LA RENON 126.0 23 % ALEMBIC 290.8 -0 % ERIS* 100.8 7%

20 MEDLEY 125.8 12 % HETERO HEALTH* 266.3 13 % RELIANCE LIFE. 98.5 38 %

Source: IQVIA TSA Dataset Aug'2024 16

West Zone Top Brands- MAT
Aug’24
Goa Gujarat Madhya Pradesh
Ran
k Value'C Growt Value'C Growt Value'C Grow
Brand Company Brand Company Brand Company
r h% r h% r th %
1 AUGMENTIN GSK* 6.4 47 % FORACORT CIPLA 50.2 25 % MONOCEF ARISTO* 61.9 9%

2 ELECTRAL FDC 3.9 23 % VIVITRA ZYDUS* 49.4 43 % DEXORANGE FRANCO 50.7 5%

3 DEXOLAC NUTRICIA 3.8 -12 % ZOSTUM EMCURE* 42.8 22 % ACILOC CADILA 48.6 13 %
PREVENAR-
4 OROFER-XT EMCURE* 3.7 39 % PFIZER* 35.2 21 % MANFORCE MANKIND 42.2 4%
13
5 SINAREST NEW CENTAUR 3.1 8 % LANTUS SANOFI* 33.8 9 % ELECTRAL FDC 39.6 3%

6 THROMBOPHOB ZYDUS* 3.0 23 % AUGMENTIN GSK* 32.0 0 % MONTAZ ARISTO* 32.3 9%

7 BETADINE WIN MEDI. 2.5 -8 % MERO ARISTO* 31.2 45 % ZIFI FDC 30.7 5%
ECOSPRIN-
8 CILACAR JB * 2.5 3% USV 30.7 -2 % LIV-52 HIMALAYA 29.4 18 %
AV
9 GLYCIPHAGE FRANCO 2.5 57 % MIXTARD ABBOTT* 30.5 -1 % ZINCOVIT APEX 27.5 13 %
WATERBURYS PIRAMAL
10 2.3 153 % RYZODEG ABBOTT* 30.0 35 % AUGMENTIN GSK* 27.1 6%
COMPOUN HEALTH.
11 VOLINI SUN* 2.3 -6 % INFLUVAC ABBOTT* 29.6 4 % PANTOP ARISTO* 27.0 23 %

12 DOLO MICRO* 2.0 12 % DUOLIN CIPLA 29.5 -1 % MIKACIN ARISTO* 26.6 2%

GLYCOMET-
13 CEFTUM GSK* 2.0 12 % DUPHASTON ABBOTT* 28.8 11 % USV 26.4 7%
GP
14 SENSODYNE GSK* 2.0 50 % RYBELSUS ABBOTT* 27.8 70 % R.B.TONE MEDLEY 26.2 28 %

15 MICROPENAM MICRO* 2.0 >500%CYRAMZA ELI LILLY 24.5 81 % FORACORT CIPLA 26.0 24 %

16 T-BACT GSK* 1.9 77 % DEXOLAC NUTRICIA 23.9 49 % CALPOL GSK* 25.7 8%

17 ATORVA ZYDUS* 1.9 -12 % BUDECORT CIPLA 23.9 -4 % TAXIM ALKEM* 25.2 18 %
RELIANCE
18 DEXORANGE FRANCO 1.9 32 % ALBUREL 23.7 -1 % LANTUS SANOFI* 24.4 -2 %
LIFE.
BRITISH GLYCOMET-
19 D-PROTIN 1.9 59 % USV 23.6 -16 % MONOCEF-O ARISTO* 23.2 9%
BIO. GP
MONOCEF-
20 FORACORT CIPLA 1.8 11 % ZIFI FDC 23.2 2% ARISTO* 21.1 16 %
SB

Maharashtra Mumbai
Rank Growth
Brand Company Value'Cr Growth % Brand Company Value'Cr
%
1 HANSAPLAST BDF 108.5 36 % IMMUNOREL RELIANCE LIFE. 64.9 65 %
2 ENERZAL FDC 102.4 38 % AUGMENTIN GSK* 49.3 -13 %
3 CLAVAM ALKEM* 75.4 2% FORACORT CIPLA 41.7 9%
4 GLYCOMET-GP USV 66.2 -2 % SHELCAL XT TORRENT * 35.8 24 %
5 FORACORT CIPLA 63.2 13 % RYBELSUS ABBOTT* 35.5 71 %
6 MIXTARD ABBOTT* 55.7 1% RYZODEG ABBOTT* 35.2 9%
7 ECOSPRIN-AV USV 54.6 9% ROSUVAS SUN* 34.5 56 %
8 AUGMENTIN GSK* 52.5 8% GLYCOMET-GP USV 32.2 2%
9 TELMA GLENMARK 50.8 36 % PAN-D ALKEM* 30.5 21 %
10 ZERODOL-SP IPCA 49.5 21 % SHELCAL TORRENT * 30.3 -6 %
11 ZIFI FDC 48.5 -0 % REJOINT NEW ABBOTT* 29.7 276 %
12 MOXIKIND-CV MANKIND 47.7 12 % OROFER-XT EMCURE* 28.6 13 %
13 PAN ALKEM* 45.7 9% MIXTARD ABBOTT* 27.2 -18 %
14 DUOLIN CIPLA 45.6 6% LANTUS SANOFI* 26.8 -28 %
15 ELECTRAL FDC 45.6 11 % NIKORAN TORRENT * 26.5 17 %
16 PAN-D ALKEM* 44.2 28 % ALBUREL RELIANCE LIFE. 25.8 0%
17 BETADINE WIN MEDI. 43.4 13 % NOVO RAPID ABBOTT* 25.3 4%
18 RYBELSUS ABBOTT* 42.2 58 % VYMADA NOVARTIS* 25.3 -31 %
19 LANTUS SANOFI* 40.4 13 % TELMA GLENMARK 23.7 -4 %
20 DUPHASTON ABBOTT* 38.3 8% MINIPRESS-XL PFIZER* 23.6 -2 %

Source: IQVIA TSA Dataset Aug'2024 17

South Zone Top Companies- MAT
Aug’24

Andhra Pradesh Karnataka Kerala

Rank Company Value'Cr Growth % Company Value'Cr Growth % Company Value'Cr Growth %
1 SUN* 821.8 6% SUN* 1,078.1 14 % SUN* 1,410.1 4%
2 ABBOTT* 544.5 7% ABBOTT* 751.6 1% ABBOTT* 838.1 9%
3 MANKIND 419.4 2% CIPLA 604.5 1% CIPLA 766.2 5%
4 CIPLA 396.3 14 % MANKIND 600.5 6% TORRENT * 463.0 11 %
5 DRL 376.2 9% MICRO* 531.0 5% ZYDUS* 460.3 2%
6 ARISTO * 354.4 2% USV 472.3 6% LUPIN 345.8 5%
7 INTAS * 297.4 8% TORRENT * 470.6 4% INTAS * 335.2 16 %
8 LUPIN 281.8 3% ALKEM* 410.6 -1 % GLENMARK 306.4 16 %
9 ALKEM* 281.1 1% LUPIN 377.7 1% MACLEODS 294.4 2%
10 MACLEODS 275.5 4% DRL 376.0 -7 % USV 290.4 20 %
11 TORRENT * 267.0 -1 % ZYDUS* 355.2 3% DRL 272.9 7%
12 ZYDUS* 226.4 7% EMCURE* 291.8 -3 % ARISTO * 262.4 5%
13 U S V 198.2 -3 % GLENMARK 291.5 23 % GSK* 227.4 -3 %
14 GLENMARK 151.4 1% GSK* 272.8 3% MICRO* 217.0 -0 %
15 EMCURE* 131.3 -1 % MACLEODS 263.9 6% MANKIND 201.2 15 %
16 IPCA LABS 127.7 8% IPCA LABS 246.7 12 % JB * 192.3 3%
17 GSK* 116.0 -7 % INTAS * 238.5 1% IPCA LABS 173.6 20 %
18 PFIZER* 110.0 -4 % ARISTO * 209.6 10 % ERIS* 159.7 6%
19 MICRO* 102.6 -2 % PFIZER* 205.0 -4 % PFIZER* 144.2 -3 %
20 JB * 98.0 4% JANSSEN 189.2 43 % BLUE CROSS 134.1 2%

Tamilnadu Telangana Chennai

Rank Company Value'Cr Growth % Company Value'Cr Growth % Company Value'Cr Growth %

1 SUN* 1,352.0 7% ABBOTT* 813.6 5% SUN* 446.4 13 %

2 CIPLA 841.3 15 % SUN* 750.3 8% ABBOTT* 312.0 7%

3 ABBOTT* 731.6 4% INTAS * 562.0 13 % DRL 235.9 8%

4 MANKIND 455.7 9% CIPLA 513.8 14 % INTAS * 195.5 21 %

5 TORRENT * 448.4 18 % DRL 477.9 13 % TORRENT * 177.8 7%

6 LUPIN 415.3 9% MANKIND 447.9 11 % LUPIN 177.0 2%

7 ZYDUS* 351.5 6% LUPIN 430.3 11 % CIPLA 168.0 -4 %

8 GSK* 309.8 -1 % TORRENT * 425.0 3% USV 165.0 9%

9 DRL 299.6 13 % ALKEM* 399.4 6% MANKIND 137.3 9%

10 ALKEM* 256.0 16 % GLENMARK 399.3 25 % GLENMARK 129.2 5%

11 GLENMARK 252.6 16 % USV 342.4 2% ALKEM* 119.9 8%

12 FOURRTS 244.0 11 % EMCURE* 341.4 24 % ZYDUS* 118.5 14 %

13 MICRO* 235.3 4% ARISTO * 275.7 15 % IPCA LABS 117.8 20 %

14 U S V 229.4 14 % MACLEODS 238.1 2% MICRO* 116.0 4%

15 PFIZER* 228.3 -1 % ZYDUS* 229.5 7% LA RENON 111.7 17 %

16 INTAS * 207.4 24 % IPCA LABS 203.3 22 % EMCURE* 105.6 7%

17 EMCURE* 198.2 1% PFIZER* 193.9 -8 % GSK* 102.7 8%

18 ERIS* 196.6 15 % SANOFI* 187.9 10 % PFIZER* 82.3 -9 %

19 ARISTO * 178.5 10 % GSK* 186.8 -3 % MERCK 80.2 98 %

20 IPCA LABS 158.4 21 % HETERO* 166.8 -10 % ERIS* 71.6 6%

Source: IQVIA TSA Dataset Aug'2024 18

South Zone Top Brands- MAT
Aug’24
Andhra Pradesh Karnataka Kerala
Rank
Value' Growth Value' Growth Value' Growth
Brand Company Brand Company Brand Company
Cr % Cr % Cr %
GLYCOMET-
1 USV 53.2 -4 % GLYCOMET-GP USV 115.9 7% MIXTARD ABBOTT* 112.4 3%
GP
2 MIXTARD ABBOTT* 48.9 1% MIXTARD ABBOTT* 73.3 -15 % FORACORT CIPLA 88.4 12 %

3 GEMER SUN* 40.4 -2 % ULTRACET JANSSEN 62.7 10 % CILACAR JB * 76.8 10 %

4 PANTOP ARISTO* 35.7 6% DARZALEX JANSSEN 60.1 162 % THYRONORM ABBOTT* 67.6 5%

5 ZINCOVIT APEX 34.7 1% DOLO MICRO* 57.4 1% GLYCOMET-GP U S V 56.6 8%

6 THYRONORM ABBOTT* 32.8 13 % THYRONORM ABBOTT* 55.1 2% AUGMENTIN GSK* 50.0 5%

7 MONOCEF ARISTO* 32.1 7% AUGMENTIN GSK* 49.3 11 % SEROFLO CIPLA 48.5 9%

8 DOLO MICRO* 28.1 -12 % LEVIPIL SUN* 46.8 21 % CONCOR MERCK 47.2 25 %

9 FORACORT CIPLA 27.8 27 % VOLINI SUN* 38.5 -7 % PANTOCID SUN* 45.2 -8 %

10 ROSUVAS SUN* 27.6 19 % ZERODOL-SP IPCA 37.6 17 % PANTOP ARISTO* 41.9 4%

11 BOSENTAS CIPLA 26.1 250 % SHELCAL TORRENT * 35.4 18 % MOXCLAV SUN* 41.1 -15 %

12 DUOLIN CIPLA 24.2 24 % FORACORT CIPLA 34.8 2% TELMA GLENMARK 39.3 25 %

13 MONOCEF-SB ARISTO* 23.5 16 % GLYCOMET TRIO U S V 34.3 -1 % ROSUVAS SUN* 38.9 1%

14 MYFAIR ZEE 23.5 -3 % ECOSPRIN-AV USV 33.4 -4 % LANTUS SANOFI* 37.5 -7 %

GLENMAR
15 TELMA-H 23.0 19 % PAN ALKEM* 32.5 13 % SHELCAL TORRENT * 32.3 -5 %
K
16 ZORYL-M INTAS * 21.5 -2 % RYZODEG ABBOTT* 32.2 -12 % BUDECORT CIPLA 31.8 12 %

17 LEVIPIL SUN* 21.0 14 % MOXIKIND-CV MANKIND 32.1 14 % JANUMET MSD* 31.8 1%

18 BUDECORT CIPLA 20.8 9% DUPHASTON ABBOTT* 32.0 9% NOVOMIX ABBOTT* 30.2 -10 %
BEPLEX
19 LUPIN 20.0 40 % CILACAR JB * 31.4 -1 % UDILIV ABBOTT* 30.0 31 %
FORTE
20 MOXIKIND-CV MANKIND 19.6 5% BUDECORT CIPLA 30.0 15 % LEVIPIL SUN* 30.0 5%

Tamilnadu Telangana Chennai

Rank
Value' Growth Value' Growth Value' Growth
Brand Company Brand Company Brand Company
Cr % Cr % Cr %
1 MIXTARD ABBOTT* 81.7 -12 % TAFFIC HETERO* 90.9 -20 % ERBITUX MERCK 58.8 157 %

2 TEDIBAR TORRENT * 56.2 26 % TELMA-H GLENMARK 81.3 56 % MIXTARD ABBOTT* 31.3 -3 %

GLYCOMET-
3 FORACORT CIPLA 53.8 16 % USV 79.5 -2 % FOLISURGE INTAS * 30.1 44 %
GP
4 ROSUVAS SUN* 50.8 14 % MIXTARD ABBOTT* 70.7 -13 % GLYCOMET-GPU S V 27.9 -5 %
GLYCOMET- RELIANCE
5 USV 49.7 4% ALBUREL 62.4 82 % RYZODEG ABBOTT* 26.2 23 %
GP LIFE.
RENERVE
6 ERIS* 49.4 13 % THYRONORM ABBOTT* 58.0 -2 % JANUMET MSD* 26.1 20 %
PLUS
7 AUGMENTIN GSK* 48.6 6% CLEXANE SANOFI* 56.0 98 % PAN ALKEM* 24.9 9%
BOEHRINGE
8 GEMER SUN* 44.6 -2 % LANTUS SANOFI* 53.3 24 % JARDIANCE 20.4 33 %
R
9 T-BACT GSK* 40.3 -9 % TELMA GLENMARK 50.9 19 % NOVOMIX ABBOTT* 20.3 -7 %

10 LEVIPIL SUN* 40.1 -13 % RYZODEG ABBOTT* 49.2 15 % PREVENAR-13 PFIZER* 20.3 18 %

11 PAN ALKEM* 37.4 31 % ERBITUX MERCK 44.3 149 % LANTUS SANOFI* 19.4 15 %

12 ZINCOVIT APEX 35.2 -1 % DOLO MICRO* 43.2 -5 % AUGMENTIN GSK* 17.6 16 %

13 VOLINI SUN* 32.8 3% NOVOMIX ABBOTT* 38.7 -22 % MABTAS INTAS * 17.6 48 %

14 ASTHALIN CIPLA 32.6 10 % OPDYTA BMS 36.2 47 % DUPHASTON ABBOTT* 17.0 -13 %

15 ELTROXIN GSK* 30.8 -3 % CLAVAM ALKEM* 33.8 5% TELMA GLENMARK 16.7 29 %

16 SUSTEN SUN* 30.4 5% ZORYL-M INTAS * 33.2 5% AZITHRAL ALEMBIC 16.2 -10 %
PREVENAR-
17 PFIZER* 29.9 22 % LEVIPIL SUN* 32.3 8% CANMAB BIOCON 16.1 61 %
13
RELIANCE
18 SUCRAFIL O FOURRTS 29.6 14 % DUPHASTON ABBOTT* 31.6 13 % RITUXIREL 15.8 244 %
LIFE.
19 TELMA-H GLENMARK 29.1 31 % PAN ALKEM* 31.5 11 % MONTEK-LC SUN* 14.1 30 %
GELUSIL- GLYCOMET
20 PFIZER* 29.0 16 % USV 31.4 -6 % CILACAR JB PHARMA * 13.9 44 %
MPS TRIO

Source: IQVIA TSA Dataset Aug'2024 19